MedTrace Logo

Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database

NCT07079644 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 678

Last updated 2025-07-23

No results posted yet for this study

Summary

The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors therapy

Conditions

Interventions

BIOLOGICAL

Nivolumab + Relatlimab

As per product label

BIOLOGICAL

Nivolumab + Ipilimumab

As per product label

BIOLOGICAL

Immunotherapy monotherapy

As per product label

DRUG

BRAF/MEK inhibitors

As per product label

Sponsors & Collaborators

Principal Investigators

  • Bristol Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-29
Primary Completion
2025-03-31
Completion
2025-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07079644 on ClinicalTrials.gov